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The antimalarial activity of chemically diverse compounds,
including the clinical candidate cipargamin, has been linked to
the ATPase PfATP4 in the malaria-causing parasite Plasmo-
dium falciparum. The characterization of PfATP4 has been
hampered by the inability thus far to achieve its functional
expression in a heterologous system. Here, we optimized a
membrane ATPase assay to probe the function of PfATP4 and
its chemical sensitivity.We found that cipargamin inhibited the
Na-dependent ATPase activity present in P. falciparummem-
branes from WT parasites and that its potency was reduced
in cipargamin-resistant PfATP4-mutant parasites. The cipar-
gamin-sensitive fraction of membrane ATPase activity was
inhibited by all 28 of the compounds in the “Malaria Box” shown
previously to disrupt ion regulation in P. falciparum in a cipar-
gamin-like manner. This is consistent with PfATP4 being the
direct target of these compounds. Characterization of the cipar-
gamin-sensitive ATPase activity yielded data consistent with
PfATP4 being a Na transporter that is sensitive to physiologi-
cally relevant perturbations of pH, but not of [K] or [Ca2].
With an apparentKm for ATP of 0.2mM and an apparentKm for
Na of 16–17 mM, the protein is predicted to operate at below
its half-maximal rate under normal physiological conditions,
allowing the rate of Na efflux to increase in response to an
increase in cytosolic [Na]. In membranes from a cipargamin-
resistant PfATP4-mutant line, the apparent Km for Na is
slightly elevated. Our study provides new insights into the bio-
chemical properties and chemical sensitivity of an important
new antimalarial drug target.
With the emergence and spread of malaria parasites that are
resistant to most of the antimalarial drugs registered for use,
there is an urgent need for the development of new antimalar-
ials. Cipargamin (previously known as KAE609 and NITD609)
is a new antimalarial currently undergoing clinical trials. In an
initial Phase 2 trial, cipargamin administered at a dose of 30mg
daily for 3 days cleared parasitemia rapidly in adults with
uncomplicated Plasmodium falciparum or Plasmodium vivax
malaria (1).
Cipargamin is a synthetic spiroindolone, first identified as an
antimalarial in a whole-cell screen of a chemical library com-
posed of some 12,000 compounds (2). Long-term in vitro expo-
sure of P. falciparum cultures to sub-lethal concentrations of
the compound led to the emergence of parasites showing low-
level resistance to cipargamin (2). These parasites were charac-
terized by mutations in PfATP4, a plasma membrane type II
P-type ATPase reported to belong to a subclass unique to api-
complexan parasites (3).
During the disease-causing stage of its life cycle, the P. falcip-
arum parasite resides in a parasitophorous vacuole within the
human erythrocyte. Like other cell types, erythrocytes normally
maintain a low internal Na concentration. However, as the
parasitematures into a trophozoite, it induces an increase in the
permeability of the erythrocyte plasmamembrane (4, 5), allow-
ing a net influx of Na that results in the erythrocyte’s cytosolic
Na concentration increasing to a level approaching that in the
extracellular medium (6–9). The parasitophorous vacuole
membrane that encloses the mature intraerythrocytic tropho-
zoite is believed to be freely permeable to lowmolecular weight
solutes and is not expected to present a barrier to the move-
ment of ions (10, 11). Thus, despite its intracellular location, the
mature trophozoite finds itself in a high-Na environment and
must effluxNa ions across its plasmamembrane tomaintain a
low cytosolic Na concentration ([Na]cyt).
There is functional evidence that PfATP4 serves as the para-
site’s primary Na-efflux pump. On addition of cipargamin or
related antimalarial spiroindolones to trophozoite-stage para-
sites, there is an increase in the parasite’s Na content (9, 12)
and [Na]cyt (13–15). The data are consistent with the spiroin-
dolones inhibiting Na extrusion via PfATP4, resulting in a net
uptake of Na as the ion moves into the parasite, down its
electrochemical gradient. The increase in [Na]cyt is accompa-
nied by an increase in cytosolic pH (pHcyt), and it has been
proposed that PfATP4 imports H into the parasite while
extruding Na (15), with inhibition of the protein resulting in a
cessation of H import and hence a cytosolic alkalinization.
To date, it has not been possible to confirm the function of
PfATP4 or to study its transport properties in a heterologous
system. In the initial description of PfATP4, it was reported that
expression of PfATP4 in Xenopus laevis oocytes gave rise to
This work was supported by an Australian Research Council Discovery Early
Career Researcher Award (DE160101035 to A. M. L.), an Australian
Research Council Linkage Project Grant (LP150101226 to K. K.), and a
National Health and Medical Research Council Project Grant (1042272 to
K. K.). The authors declare that they have no conflicts of interest with the
contents of this article.
This article was selected as one of our Editors’ Picks.
1 To whom correspondence may be addressed. Tel.: 61-2-6125-0421; E-mail:
kiaran.kirk@anu.edu.au.
2 To whom correspondence may be addressed. Tel.: 61-2-6125-6970; E-mail:
adele.lehane@anu.edu.au.
croEDITORS’ PICK
J. Biol. Chem. (2018) 293(34) 13327–13337 13327
© 2018 Rosling et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
 at A
ustralian N
atl U
niv (CAUL) on January 6, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
increased Ca2-dependent ATPase activity (3); however, at
least one other laboratory has been unable to reproduce this
finding or to achieve functional expression of the transporter
(2).
In the last few years, numerous chemically diverse com-
pounds have been shown to disrupt parasite ion regulation in
the same manner as that seen for the antimalarial spiroindolo-
nes (13, 14, 16–19), including 28 compounds from the Medi-
cines for Malaria Venture’s (MMV’s)3 “Malaria Box” (18) and
11 compounds from the MMV’s “Pathogen Box” (13). A num-
ber of these compounds have been used to select for resistant
parasites, and in each case resistancewas associatedwith one or
two mutations in PfATP4 (14, 17–19).
With only indirect assays available, and with an increasingly
large number of diverse chemotypes displaying “PfATP4-asso-
ciated” activity, the question arises of whether PfATP4 is the
direct target of all of the PfATP4-associated compounds (20). It
is conceivable that certain compounds could perturb cellular
physiology or other proteins in such a way as to inhibit PfATP4
indirectly. The most direct evidence for inhibition of PfATP4
by an antiplasmodial compound comes from studies with
membrane preparations. Spillman et al. (15) prepared mem-
branes from isolated asexual blood-stage parasites and demon-
strated the presence in this preparation of a Na-dependent
ATPase activity that was inhibited by the antimalarial spiroin-
dolone NITD246. The sensitivity of this ATPase activity to
inhibition by NITD246 was reduced in membranes prepared
from spiroindolone-resistant parasites carrying mutations in
PfATP4, consistent with the ATPase activity being associated
with PfATP4. Recently, the 11 PfATP4-associated Pathogen
Box compounds have also been shown to inhibit Na-depen-
dent ATPase activity in parasite membrane preparations (13).
In this study, we have carried out a detailed biochemical
characterization of the PfATP4-associated ATPase activity in
membranes of blood-stage P. falciparum parasites, and we
investigated whether this activity is inhibited by the diverse
Malaria Box compounds shown previously (18) to perturb Na
and pH homeostasis in the parasite.
Results
Inhibition of Na-dependent ATPase activity in parasite
membranes by cipargamin
In the initial experiments of this study, the lead spiroin-
dolone cipargaminwas tested (at a concentration of 500 nM) for
its effect on the time course of ATP hydrolysis by isolated par-
asite membranes, measured both in the presence of a high (152
mM) and low (2 mM) concentration of Na. The organic cation
choline was used to replace Na in the low-[Na] medium. By
adding ATP to initiate the reaction, it was necessary to use
Na2ATP as we found that the commercially available K and
Mg2 salts of ATP both had significant Pi contamination (as
reported previously (15)). It was therefore not possible to per-
form measurements in the complete absence of Na.
As is illustrated in Fig. 1a, the amount of Pi produced as a
result of ATP hydrolysis increased approximately linearly with
time for the first 10 min under all the conditions tested, before
starting to slow. The Pi productionmeasured in the high-[Na]
medium in the absence of cipargamin was higher than that
measured under any of the other conditions tested. At the
10-min time point, Pi production in the low-[Na] condition in
the presence of solvent alone (0.4% v/vDMSO)was 78.1 0.5%
(mean S.D.; n 3) of that seen in the high-[Na] condition
(p  0.001, paired t test). This value is very similar to that
reported previously (76% (15)). Cipargamin (tested at 500 nM)
decreased Pi production in the high-[Na] condition to 72.8
0.6% (mean  S.D.; n  3) of the control value (p  0.001,
paired t test). Cipargamin also caused a slight but statistically
significant decrease in Pi production in the low [Na] condition
(p 0.03, paired t test); this most likely results from inhibition
of the residual Na-ATPase activity that is present in the 2 mM
Namedium. The ATPase activities measured in the high- and
low-[Na] media in the presence of cipargamin were not sig-
nificantly different from one another (p  0.3, paired t test),
consistent with 500 nM cipargamin having eliminated 100% of
the Na-ATPase activity (i.e. there is no Na-dependent com-
ponent to the ATPase activity when 500 nM cipargamin is
present).
PfATP4 has been proposed to function as a Na efflux trans-
porter and to be the target of antimalarial spiroindolones (15).
Henceforth, in this study, the cipargamin-sensitive Na-AT-
Pase activity in P. falciparum membranes (calculated by sub-
tracting the amount of Pi produced in the presence of 500 nM
cipargamin from that obtained in its absence) is used as a proxy
for PfATP4 activity and is referred to as “PfATP4-associated
ATPase activity.”
Under the conditions of our experiments, the amount of Pi
produced by PfATP4-associated ATPase activity increased
approximately linearly with time for the first 15 min before
starting to slow (Fig. 1b). In subsequent experiments, the rate of
Pi productionwas estimated using a single time point. For those
experiments in which the effects ofMalaria Box compounds on
3 The abbreviations used are: MMV, Medicines for Malaria Venture; ANOVA,
analysis of variance.
Figure1. Timecourse forPiproductionbyATPases inP. falciparummem-
branes.a,amountof Pi producedbyP. falciparummembraneswasmeasured
under high-[Na] (152 mM) and low-[Na] (2 mM) conditions in the presence
and absence of 500 nM cipargamin. b, amount of Pi produced in the high-
[Na] condition in the presence of cipargamin was subtracted from that
obtained in the high-[Na] condition in the absence of cipargamin to deter-
mine the “PfATP4-associated ATPase activity.” The dashed line indicates the
amount of Pi that would be produced if PfATP4-associated ATPase activity
continued at the initial rate for the duration of the experiment. The datawere
obtained with Dd2 parasites and are shown as the mean ( S.D.) from three
independent experiments, each performed on different days with different
membrane preparations. Where not shown, the error bars fall within the sym-
bols. The ATP concentration was 1 mM.
PfATP4-associated Na-ATPase activity in Plasmodium
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PfATP4-associated ATPase activity were investigated, we used
a time point of 15 min. For those experiments in which it was
essential that PfATP4-associated ATPase activity was mea-
sured at its maximal rate (e.g. kinetic measurements), we used a
time point of 10 min.
Inhibition of Na-dependent ATPase activity in parasite
membranes by diverseMalaria Box compounds
We investigated the effects on the parasite’s Na-dependent
ATPase activity of 28 compounds from theMalaria Box shown
previously (18) to give rise to the “ionic signature” of PfATP4
inhibition (i.e. an increase in both [Na]cyt and pHcyt and a
reduction in the level of cytosolic acidification seen following
inhibition of the V-type H-ATPase with concanamycin A).
Like cipargamin, each of the 28 PfATP4-associated compounds
from the Malaria Box (tested at 4 M) significantly inhibited Pi
production in the high-[Na] condition; at the concentrations
tested here only two of the compounds (MMV000642 and
MMV008455) gave rise to statistically significant effects in the
low-[Na] condition (Fig. S1). Fig. 2 shows the effect of each
compound on the Na-dependent ATPase activity of parasite
membranes (calculated by subtracting the amount of Pi pro-
duced in the low-[Na] medium from that produced in the
high-[Na] medium). Each of the 28 PfATP4-associated
Malaria Box compounds (tested at 4 M) effectively eliminated
the Na-dependent ATPase activity in parasite membranes
(Fig. 2). Two Malaria Box compounds (MMV007839 and
MMV000972) that do not display the ionic signature of PfATP4
inhibition and that have been found to inhibit the unrelated
(non-ATP-hydrolyzing) P. falciparum lactate/H transporter
PfFNT (21) were included as controls. Neither of these com-
pounds (each tested at 4 M) affected Na-dependent ATPase
activity (Fig. 2).
We also tested each of the 28PfATP4-associatedMalaria Box
compounds, as well as the control compounds MMV007839
and MMV000972, for their effects on ATPase activity when
added to membrane preparations that were simultaneously
exposed to 500 nM cipargamin (a concentration that completely
eliminates Na-ATPase activity; Fig. 1). The majority of the
PfATP4-associated Malaria Box compounds did not cause any
further inhibition of ATPase activity when tested in the pres-
ence of 500 nM cipargamin (Fig. S1), consistent with their
effects on Pi production (as measured in the absence of cipar-
gamin; Fig. 2) being due wholly to inhibition of the same
ATPase as is targeted by cipargamin. The PfATP4-associated
Malaria Box compounds MMV000642 and MMV008455 were
exceptions, decreasing Pi production significantly in the pres-
ence of cipargamin under both high-[Na] and low-[Na] con-
ditions (Fig. S1). This suggests that these compounds inhibit
one or more Na-independent ATPases in addition to inhibit-
ing Na-dependent ATPase activity. Three other PfATP4-as-
sociatedMalaria Box compounds (MMV006427,MMV000662,
and MMV396719) caused minor decreases in ATPase activity in
the presence of 500 nM cipargamin, with these decreases attaining
statistical significance in the high-[Na] condition but not in the
low-[Na] condition (Fig. S1).Theseminor effectswerenot inves-
tigated further.Thecontrol (non-PfATP4-associated)compounds
MMV007839 andMMV000972 had no effect on ATPase activity
under any of the conditions tested (Fig. S1).
Estimation of the affinity of PfATP4 for ATP
The ATP concentration dependence of total membrane
ATPase activity (Fig. 3, inset) and PfATP4-associated ATPase
activity (Fig. 3) was measured over 10 min in media containing
high [Na] (150–153 mM depending on the concentration of
Na2ATP). Both the total membrane ATPase activity and the
PfATP4-associated ATPase activity increased with increasing
[ATP],with both reaching amaximal rate at an [ATP] of1mM
(Fig. 3). Fitting the Michaelis-Menten equation to the data for
PfATP4-associated ATPase activity (Fig. 3) yielded a Km for
ATP (Km(ATP)) of 0.23 0.06 mM (mean S.D.; n 4). The
Vmax for PfATP4-associated Pi production under the condi-
tions tested was 24  5 nmol/min/mg of protein (noting that
the protein measurement includes all protein present in the
membrane preparation).
All subsequent experiments for which results are reported
belowwere performed over 10min with an [ATP] of 1mM. The
use of 1 mM ATP led to a concentration of 2 mM Na in the
low-[Na] measurements. The pH of the reaction solutions
(after the addition of 1 mMATP) was 7.2, which corresponds to
the estimated pHcyt in intraerythrocytic P. falciparum parasites
(22).
Figure 2. Effects of various compounds onP. falciparumNa-dependent
ATPase activity. The data were obtained by subtracting the amount of Pi
produced in the low-[Na] (0.5mM)medium from that produced in the high-
[Na] (125.5 mM) medium. Cipargamin was tested at a concentration of 500
nM; the other compounds (all from the Malaria Box, with 28 of them (white
bars) having PfATP4-associated activity and two of them, MMV007839 and
MMV000972 (gray bars), having activity against an unrelated transport pro-
tein)were testedat a concentrationof 4M. The crosses indicate thedata from
the individual independent biological replicates. The ATP concentration was
0.25mM; thepHwas7.4; and thedurationof the reactionwas15min. Thedata
were obtained with Dd2 parasites and are shown as the mean ( or S.D.)
from three to five independent experiments, each performed on different
dayswithdifferentmembranepreparations. Theprotein contentof themem-
brane preparations was not quantified in these experiments; each reaction
well contained membrane from 3 106 cells. For each compound, the data
were tested for statistical significance compared with the control (red bar;
0.4% v/v DMSO) using a one-way ANOVA (which yielded an F probability
0.001) followedby apost hoc least significant difference test; ***,p 0.001.
PfATP4-associated Na-ATPase activity in Plasmodium
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Estimation of the affinity of PfATP4 for Na
We next sought to determine the affinity of PfATP4 for Na
by measuring PfATP4-associated ATPase activity in media
having a range of [Na]. Both the total membrane ATPase
activity (Fig. 4, inset) and the PfATP4-associated ATPase activ-
ity (Fig. 4) increased with increasing [Na]. In the presence of
500 nM cipargamin, there was little effect of [Na] on the
remaining fraction of membrane ATPase activity (Fig. 4, inset).
Fitting aMichaelis-Menten curve to the data for PfATP4-asso-
ciated ATPase activity yielded a Km for Na (Km(Na)) of
16.1  3.8 mM (mean  S.D.; n  8). The Vmax under the
conditions of these experiments was 21.8  3.8 nmol of Pi per
mg of (total) protein per min.
We investigated the Na dependence of PfATP4-associated
ATPase activity over a range of different [ATP] (Fig. S2). Con-
sistent with our findings with membranes in a high-[Na]
medium (Fig. 3), PfATP4-associated ATPase activity decreased
as the [ATP] was reduced below 1 mM at each of the [Na]
tested (Fig. S2). The Km(Na) at the lowest [ATP] (0.25 mM)
was 1.4-fold higher than that at the highest [ATP] tested (1mM;
Fig. S2).
Effect of pH, [K], and [Ca2] on PfATP4-associated ATPase
activity
The effect of pH, [K], and [Ca2] on total P. falciparum
membrane ATPase activity and on PfATP4-associated ATPase
activity was investigated, with measurements performed under
both high-[Na] and low-[Na] conditions in the presence and
absence of cipargamin (500 nM). The data are shown in Fig. 5,
a–f; the p values cited in this section are from the least signifi-
cant difference tests that proceeded one-way ANOVAs per-
formedwith all the data containedwithin each panel (theANO-
VAs yielded F probabilities0.05 for Fig. 5, a–c, e, and f).
ATPase activitywasmeasured at four different pHvalues: pH
5.6, 6.6, 7.2, and 7.6. Between pH 5.6 and 7.2, total membrane
ATPase activity increasedwith increasing pHvalues under each
of the conditions tested (p 0.001, compared with the activity
at pH5.6; Fig. 5a). In the high-[Na] condition in the absence of
cipargamin,membraneATPase activity increased furtherwhen
the pH was increased from 7.2 to 7.6, although the difference
was not significant (p 	 0.05; Fig. 5a). In contrast, membrane
ATPase activity measured in the presence of cipargamin and in
the low-[Na] conditions decreased slightly (but not signifi-
cantly; p	 0.05)when the pHwas increased from7.2 to 7.6 (Fig.
5a).
As shown in Fig. 5b, the PfATP4-associated ATPase activity,
calculated by subtracting the total ATPase activity measured in
the presence of 500 nM cipargamin from that measured in the
absence of cipargamin, increased with increasing pH values
over the full pH range tested. The increase was statistically sig-
nificant (p  0.01) for all pairwise comparisons except for the
pH 7.2 versus 7.6 comparison (p	 0.05).
Figure 3. [ATP] dependence of PfATP4-associated ATPase activity under high-[Na] (150–153mM) conditions. The PfATP4-associated ATPase activity
(white circles) was calculatedby subtracting the total ATPase activitymeasured in the presence of 500 nM cipargamin (inset, black triangles) from thatmeasured
in the absence of cipargamin (inset, black circles). The data were obtained with Dd2 parasites and are shown as the mean ( S.D.) from four independent
experiments, each performed on different days with different membrane preparations. For reasons of clarity, only upward error bars are shown for the data
obtained in the absence of cipargamin (inset), and only downward error bars are shown for the data obtained in the presence of cipargamin (inset). Where not
shown, the error bars fallwithin the symbols. The additionofATP to the reactionmixtureswas found togive rise tominor effects onpH,with thepHvarying from
7.4 in the absence of ATP to 7.2 in the presence of the highest [ATP] tested. The PfATP4-associated ATPase activity data were fitted with theMichaelis-Menten
equation (PfATP4-associated ATPase activity Vmax [ATP]/([ATP] Km(ATP))), yielding a Km(ATP) of 0.23 0.06 mM and a Vmax of 24 5 nmol/min/mg of
protein (mean S.D.).
PfATP4-associated Na-ATPase activity in Plasmodium
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As well as measuring the pH dependence of ATPase activity
under high- and low-[Na] conditions (Fig. 5a), we investigated
the Na dependence of PfATP4-associated ATPase activity
over a range of different pH values (Fig. S3). The Km(Na)
decreased with increasing pH values (in the range 5.6 to 7.6),
consistent with the affinity of PfATP4 for Na increasing
with increasing pH values over this range (Fig. S3). The Vmax
for PfATP4-associated ATPase activity also increased with
increasing pH values (Fig. S3).
Experiments in which [K] was varied over the range 0–150
mM revealed that [K] had little effect on total membrane
ATPase activity under any of the conditions tested (Fig. 5c).
There was a slight but significant increase in ATPase activity
(relative to that observed in the absence ofK) in the low-[Na]
conditions in the presence of 15–120 mM K (p  0.05, com-
pared with the activity with K  0 mM). The PfATP4-associ-
ated ATPase activity was unaffected by [K] over the full range
of concentrations tested (Fig. 5d; p	 0.05).
In experiments in which free [Ca2] was varied between 0
and 1mM, there were two effects of [Ca2] on the total ATPase
activity associatedwithmembranes isolated fromP. falciparum
parasites. First, there was a very slight but statistically signifi-
cant increase in ATPase activity in the presence of 1.6–40 M
Ca2 (p 0.05 for all conditions, compared with the activity at
[Ca2] 0mM). Thiswas seen under both high- and low-[Na]
conditions and suggests that there may be at least one func-
tional Ca2-dependent ATPase in the membrane preparation.
Second, at the highest concentration tested (1 mM), Ca2 had
an inhibitory effect on ATPase activity under all of the condi-
tions tested (Fig. 5e; p  0.001, compared with the activity at
[Ca2]  0 mM). The PfATP4-associated ATPase activity
showed just the second of the two effects (Fig. 5f); Ca2 inhib-
ited PfATP4-associated ATPase activity significantly at the
highest concentration tested (1 mM; p  0.01), but it had no
significant effect on PfATP4-associatedATPase activity at con-
centrations 200 M (p 	 0.05). The PfATP4-associated
ATPase activity is therefore not dependent on Ca2 but is sus-
ceptible to inhibition by Ca2 at high concentrations.
Sensitivity of PfATP4-associated ATPase activity to cipargamin
inWT and PfATP4-mutant parasites
We investigated the concentration dependence of the inhi-
bition of PfATP4-associated ATPase activity by cipargamin in
two different pairs of parasite lines: (i) a Dd2 mutant parasite
line with a T418N mutation in PfATP4 (Dd2-PfATP4T418N),
generated by selectionwith the PfATP4-associatedMalaria Box
compoundMMV007275 (18) and then cloned by limiting dilu-
tion, together with its Dd2 parental line; and (ii) the spiroin-
dolone-selected line NITD609-RDd2-clone 2 (from Ref. 2 with
T418N and P990Rmutations in PfATP4 and referred to here as
Dd2-PfATP4T418N,P990R) together with its Dd2 parental line.
The IC50 for growth inhibition by cipargamin was 5-fold higher
Figure 4. [Na] dependence of PfATP4-associatedATPase activity. The PfATP4-associatedATPase activity (white circles) was calculated as described under
“Experimental procedures” using the total ATPase activity measured in the presence of 500 nM cipargamin (inset, black triangles) and that measured in the
absence of cipargamin (inset, black circles). The data were obtained with Dd2 parasites and are shown as the mean ( S.D.) from eight independent experi-
ments, each performed on different dayswith differentmembrane preparations. For reasons of clarity, only upward error bars are shown for the data obtained
in the absenceof cipargamin (inset), andonlydownward error bars are shown for thedataobtained in thepresenceof cipargamin (inset). ThePfATP4-associated
ATPase activity data were fitted with the Michaelis-Menten equation (PfATP4-associated ATPase activity  Vmax  [Na
]/([Na]  Km(Na
))), yielding a
Km(Na
) of 16.1 3.8 mM and a Vmax of 21.8 3.8 nmol/min/mg of protein (mean S.D.).
PfATP4-associated Na-ATPase activity in Plasmodium
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in Dd2-PfATP4T418N parasites than in their parental parasites
and 16-fold higher in Dd2-PfATP4T418N,P990R parasites than in
their parental parasites (Table 1; Fig. 6).
In membranes prepared from Dd2 parental parasites, cipar-
gamin inhibited PfATP4-associated ATPase activity with an
IC50 of 12.3  3.3 nM for the parent of Dd2-PfATP4T418N and
13.9 1.4 nM for the parent of Dd2-PfATP4T418N,P990R (Table
1; Fig. 6). These values are 15–21-fold higher than the IC50
values for cipargamin in parasite proliferation assays with these
lines (Table 1). The potency with which cipargamin inhibited
PfATP4-associated ATPase activity was decreased by 1.7-fold
in membranes prepared from Dd2-PfATP4T418N parasites rel-
ative to their parental parasites and by 2.3-fold in membranes
prepared from Dd2-PfATP4T418N,P990R parasites relative to
their parental parasites (both decreases were statistically signif-
icant; Table 1; Fig. 6).
Cipargamin therefore inhibits parasite growth somewhat
more potently than it inhibits PfATP4-associated ATPase
activity in the isolated membrane assay used here, and a
decrease in parasite susceptibility to cipargamin is associated
with a reduced sensitivity of PfATP4-associated ATPase activ-
ity to the drug. The higher level of resistance to inhibition of
parasite proliferation by cipargamin inDd2-PfATP4T418N,P990R
parasites relative to Dd2-PfATP4T418N parasites was associated
with a significantly higher level of resistance of PfATP4-associ-
ated ATPase activity to cipargamin in the former relative to the
latter line (p  0.002, unpaired t test; Table 1). This provides
further evidence that the PfATP4-associated ATPase activity
measured here corresponds to the activity of the PfATP4
protein.
Affinity of PfATP4 for Na inWT and cipargamin-resistant
parasite lines
The affinity of PfATP4 for Na was investigated in Dd2-
PfATP4T418N,P990R parasites and their matched parental para-
sites. In Dd2-PfATP4T418N,P990R parasites, we estimated a
Km(Na) of 22 7mM (mean S.D.), significantly higher than
that measured with the Dd2 parental parasites (16.5 3.3 mM;
p 0.04, paired t test; Fig. 7). These data are consistent with the
combination of the T418N and P990R mutations in PfATP4
reducing the affinity of the transporter for Na. The Vmax for
PfATP4-associatedATPase activity was not significantly differ-
ent between the two lines: 22.5 3.2 nmol of Pi permg of (total)
protein per min (mean  S.D.) in the parental parasites and
22.3  2.6 nmol of Pi per mg of (total) protein per min in the
Dd2-PfATP4T418N,P990R parasites (p 0.87, paired t test).
Discussion
The finding that the activity of numerous diverse antiplas-
modial chemotypes can be linked to one protein, PfATP4, is
unexplained. To date, there is no system for studying PfATP4
activity in isolation, and it has not been possible to determine
whether the numerous PfATP4-associated compounds that
have been shown to disrupt Na and pH regulation in parasites
and to be rendered less potent by mutations in PfATP4 act via
direct inhibition of PfATP4. The lack of a direct assay to study
PfATP4 has also hampered investigations into its transport
characteristics. Here, we have optimized a cell-free assay in
Figure 5. Effect of pH (a and b), [K] (c and d), and [Ca2] (e and f) on
membraneATPase activity andPfATP4-associatedATPase activity. Total
ATPase activity (a, c, and e) was measured under high-[Na] (black) and low-
[Na] (red) conditions and in the presence (triangles) and absence (circles) of
cipargamin (500 nM). PfATP4-associated ATPase activity (b, d, and f) was cal-
culated by subtracting the (pre-normalized) data obtained in the presence of
cipargamin (and a high [Na]) from those obtained in the high-[Na] condi-
tion in the absence of cipargamin. Thedatawere obtainedwithDd2parasites
and are shown as the mean ( S.D.) from three independent experiments,
each performed on different days with different membrane preparations.
Where not shown, the error bars fall within the symbols. In the experiments in
which [K] was varied, [choline] was also varied such that [KCl]  [choline
chloride]  150 mM in the high-[Na] condition. Choline was also used to
replace Na in the low-[Na] condition. e and f, [Ca2] indicated corresponds
to free [Ca2] and was determined by adding 1 mM EGTA to the reaction
mixture aswell as sufficient CaCl2 to achieve the desired free [Ca
2] (Ca-EGTA
Calculator v1.3).
Table 1
Potency of cipargamin against parasite proliferation and PfATP4-as-
sociated ATPase activity in two PfATP4-mutant lines and their paren-
tal lines
The data presented are the mean IC50  S.D. from the number of experiments
indicated in parentheses. *, p  0.05; **, p  0.01; ***, p  0.001 (t-tests compared
with matched parental line, paired or unpaired as appropriate).
Cipargamin IC50 (nM)
Parasite
proliferation
PfATP4-associated
ATPase activity
Parent of Dd2-PfATP4T418N 0.84 0.17 (n 6) 12.3 3.3 (n 4)
Dd2-PfATP4T418N 4.3 0.5 (n 6)*** 21.1 3.0 (n 5)**
Parent of Dd2-PfATP4T418N,P990R 0.66 0.09 (n 3) 13.9 1.4 (n 3)
Dd2-PfATP4T418N,P990R 10.6 2.2 (n 3)* 32.5 3.2 (n 3)**
PfATP4-associated Na-ATPase activity in Plasmodium
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which the ATPase activity present in P. falciparummembrane
preparations is measured under varying conditions and, using
the cipargamin-sensitive fraction of ATPase activity as a proxy
for PfATP4 activity, have characterized the biochemical prop-
erties of the protein.
Approximately one-quarter of the ATPase activity measured
inP. falciparummembraneswasNa-dependent. This fraction
was inhibited by the spiroindolone cipargamin, the best-stud-
ied and most clinically advanced of the PfATP4-associated
compounds. These data are consistent with those obtained
previously with spiroindolones (13, 15) and suggest that the
majority, if not all, of the Na-dependent ATPase activity in
P. falciparum membranes is contributed by PfATP4. Of note,
cipargamin has been found to inhibit directly the ATPase activ-
ity of a H-transporting P-type ATPase from Saccharomyces
cerevisiae (23).
The IC50 value for cipargamin against PfATP4-associated
ATPase activity in isolated membranes was somewhat higher
than its IC50 value for parasite killing (3–21-fold higher in our
study, depending on the parasite line). This is in line with a
previous study (15), which found that a different spiroindolone,
NITD246, was more potent against parasite growth than
against the parasite’s Na-dependent ATPase activity, although
in the previous study the fold differences were lower ( 2-fold).
There are many potential explanations for a difference in the
potency of a compound against its target and against a whole
organism. It is possible that a relatively small reduction in
PfATP4 activity might have a relatively large effect on parasite
growth. It is also possible that in the parasite growth experi-
ments cipargamin accumulates at its site of action to concen-
trations higher than those present in the extracellular media. It
should also be noted that in our experiments inhibition of the
Figure 6. Potency of cipargamin against parasite growth (red curves) and PfATP4-associated ATPase activity (black curves) in PfATP4-mutant lines
and their parents. The data for Dd2-PfATP4T418N and its parent (a) and Dd2-PfATP4T418N,P990R and its parent (b) were obtained from the number of indepen-
dent experiments indicated inTable1, and theyare shownas themeanS.D.Wherenot shown, the error bars fallwithin the symbols. Parasiteproliferationdata
for the PfATP4-mutant lines (gray symbols) and their parental lines (white symbols) are shown with diamonds and red lines, and data for PfATP4-associated
ATPase activity are shown with circles and black lines. For clarity, only upward error bars are shown for data obtained with the PfATP4-mutant lines, and only
downward error bars are shown for data obtained with the parental lines. ATPase activity was determined at pH 7.2 in the presence of 152 mM Na and 1 mM
ATP. In each case the data were fit to a sigmoidal curve: y a/(1 ([cipargamin]/IC50)
b, where a is the maximum y value, and b is a fitted constant.
Figure 7. Effect of [Na] onPfATP4-associatedATPase activity inDd2-PfATP4T418N,P990R parasites (gray) and their parental parasites (white). Thedata
are shown as themean ( or S.D.) from 10 independent experiments, each performed on different days with different membrane preparations. The curves
were drawnusing theMichaelis-Menten equation (PfATP4-associatedATPase activityVmax [Na
]/([Na] Km(Na
))) fitted to the data. The Km(Na
) in the
two lines (shown as themean S.D.) from the same experiments are shown as an inset, with Km values from each individual experiment shownwith a cross. *,
p 0.05, paired t test.
PfATP4-associated Na-ATPase activity in Plasmodium
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Na-dependentATPase activitywasmeasured under high (152
mM) [Na] conditions and that thismay have resulted in higher
IC50 values than would be the case if inhibition were to bemea-
sured under the lower [Na] conditions that prevail in the cyto-
sol of the parasite under resting conditions (7–15 mM).
Consistent with a previous finding with NITD246 (15), the
potency of cipargamin against PfATP4-associated ATPase
activity was reduced in PfATP4-mutant parasites. The double
mutant line (Dd2-PfATP4T418N,P990R) was more resistant to
growth inhibition by cipargamin than the single mutant line
(Dd2-PfATP4T418N) and also displayed a higher level of resis-
tance to inhibition of PfATP4-associated ATPase activity by
cipargamin. The fold-increase in the IC50 for cipargamin
against PfATP4-associated ATPase activity that was conferred
by the PfATP4 mutation(s) (1.7–2.3-fold) was lower than that
observed for growth inhibition (5–16-fold). It is possible that
the high [Na] conditions may have masked differences in
cipargamin sensitivity between WT and mutant proteins that
exist under physiological conditions. Alternatively, it is possible
that factors other than a reduced interaction of PfATP4 and
cipargamin contribute to parasite resistance in the PfATP4-
mutant lines investigated.
The Na-dependent fraction of P. falciparum membrane
ATPase activity was inhibited by all 28 of theMalaria Box com-
pounds that had previously been shown to disrupt ion homeo-
stasis in P. falciparum in a spiroindolone-like manner (18). In
light of this finding, certain scenarios (20) that might have
explained the activity of the compounds can now be excluded.
Specifically, our data are not consistent with models whereby
the compounds act by: (i) interferingwith PfATP4 trafficking or
localization to the plasma membrane; (ii) inhibiting a non-
membrane-associated protein that modulates PfATP4 activity;
(iii) altering cell pH by a mechanism not involving PfATP4
(with a change in PfATP4 activity being a downstream conse-
quence); and (iv) rendering the parasite plasmamembrane per-
meable toNa (i.e. behaving as aNa ionophore, with a change
in pH being a downstream consequence, and mutations in
PfATP4 having a compensatory function in resistant parasites).
Our data are consistent with the simplest model, whereby the
PfATP4-associated compounds bind directly to PfATP4 and
inhibit its normal function. However, our data do not rule out
the possibility that someof the compounds affect PfATP4 activ-
ity by inhibiting a membrane-associated regulator of its func-
tion or by altering the physical properties of the membrane in
such a way as to alter PfATP4 function.
Our optimized assay enabled a characterization of the kinetic
properties and ion dependence of PfATP4-associated ATPase
activity. Our finding that PfATP4-associated ATPase activity
increasedwith increasing [Na] is consistentwith other lines of
evidence (9, 15) that PfATP4 serves as a Na pump. We esti-
mated the affinity of PfATP4 for Na by measuring the cipar-
gamin-sensitive fraction of ATPase activity at a range of [Na]
and fitting a Michaelis-Menten curve to the data. Under the
conditions of our experiments, pH 7.2, we estimated that WT
PfATP4 (as measured in two Dd2 clones originating from dif-
ferent laboratories) has a Km(Na) of 16–17 mM. The resting
[Na]cyt in Dd2 parasites is 7 mM (15). Thus, under resting
conditions the ATPase is predicted to be operating at30% of
its maximum activity and therefore to have the capacity to
increase its activity (i.e. increase the rate of Na efflux) by up to
3.2-fold in response to an increase in [Na]cyt. The Na Km
value determined here for PfATP4 is within the range of Na
Km values that have been reported for different isoforms of the
Na/K pump that control [Na]cyt in human cells (8–33 mM
(24, 25)) and is slightly lower than that estimated for a P-type
Na-ATPase in Leishmania amazonensis parasites (29 mM)
(26).
Our investigation of the Na dependence of PfATP4-associ-
ated ATPase activity with cipargamin-resistant parasites
yielded evidence that the resistance-associated double-mutant
(T418N,P990R) variant of PfATP4 has a reduced affinity for
Na (22 mM) compared with WT PfATP4, with no discernible
effect of the mutations on the Vmax of the transporter. This
provides a potential explanation for the observation that
[Na]cyt is elevated in Dd2-PfATP4T418N,P990R parasites rela-
tive to their parental parasites (15). The [Na]cyt measured in
Dd2-PfATP4T418N,P990R was 15 mM, compared with an esti-
mated value of 7 mM in the parental parasites (15).
The Km(ATP) estimated for PfATP4 (0.2 mM) is much lower
than typical intracellular ATP concentrations, including the
intracellular ATP concentration that has been estimated for
P. falciparum parasites (2.5 mM) (27). Thus, the ATP concen-
tration inside the parasite should not be limiting for PfATP4
activity, and fluctuations in [ATP] within the physiological
range will have little effect on its transport rate.
Previous studies have shown that antiplasmodial spiroindo-
lones and other PfATP4-associated compounds increase pHcyt
in P. falciparum (i.e. increase the pH gradient across the para-
site plasmamembrane) (15–19), prompting the suggestion that
PfATP4 imports H while exporting Na (15). pH can affect
the activity of proteins in a variety of ways through its effects on
protonatable residues and in some cases also by H (or OH)
being a substrate and/or allosteric activator or inhibitor. Thus,
calculating a Km value for H transport is not straightforward
and was not attempted here. Nevertheless, our finding that
PfATP4 activity increased with increasing pH raises the possi-
bility that the protein is regulated by pH; if the region of the
protein responsible for the pH dependence of PfATP4-associ-
ated ATPase activity seen here is exposed to the parasite cyto-
sol, the protein could respond to a cytosolic alkalinization by
undergoing an increase in activity, importing H into the par-
asite at an increased rate.
PfATP4 was originally annotated as a Ca2 transporter, and
its expression in Xenopus oocytes was reported to increase the
Ca2-dependent ATPase activity present in oocytemembranes
(3). However, others were not able to observe a Ca2-depen-
dent ATPase activity when attempting to reproduce this result
(2), and the addition of an antiplasmodial spiroindolone to iso-
lated parasites was without effect on [Ca2]cyt (15). Our finding
that Ca2 did not stimulate the parasite’s cipargamin-sensitive
ATPase activity provides further evidence that PfATP4 is not a
Ca2 transporter. Therewas a slight stimulation of cipargamin-
insensitive ATPase activity at [Ca2] between 1.6 and 40 M,
consistent with there being one or more Ca2-ATPases in par-
asite membranes that could be characterized using a similar
approach to that used here to study PfATP4. At the highest
PfATP4-associated Na-ATPase activity in Plasmodium
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concentration tested (1 mM), Ca2 was found to inhibit
PfATP4-associated ATPase activity as well as the activity of
other (Na-independent, cipargamin-insensitive) ATPases.
Inhibition of various ATPases by millimolar [Ca2] has been
reported in previous studies (28, 29), and it may be explained at
least in part by Ca2 competing withMg2 for protein binding
(28).
Kwaswithout effect on PfATP4-associatedATPase activity
when present at concentrations ranging from 0 to 150mM. The
slight stimulation of membrane ATPase activity in low [Na]
conditions by [K] of 15–120mM suggests that theremay be an
active K-dependent ATPase in parasite membranes.
The system described here to study PfATP4 is more direct
than whole-cell approaches, and it enables the precise control
of experimental conditions required to characterize PfATP4
function and drug interactions. The assay will enable an evalu-
ation of the function of mutant forms of the PfATP4 protein
that arise in the laboratory or the field and the determination of
whether (and how potently) antiplasmodial compounds inhibit
different variants of the transporter.
Experimental procedures
Ethics statement
The use of human blood in this study was approved by the
Australian National University Human Research Ethics Com-
mittee. The blood was provided by the Australian Red Cross
Blood Service without revealing the identities of the donors.
The donors signed an agreement with the Blood Service grant-
ing permission for their blood to be used for medical research.
Parasite culture and isolation
Unless stated otherwise, a cloned Dd2 line (the parent of
Dd2-PfATP4T418N, generated from the Dd2 strain by limiting
dilution (30)) was used throughout this study. In a previous
study (18), the cloned Dd2 parasites were exposed to the
PfATP4-associated Malaria Box compound MMV007275,
yielding MMV007275-resistant parasites (18). The Dd2-
PfATP4T418N parasite line for which data are shown in Fig. 6
and Table 1 was obtained from theMMV007275-resistant bulk
culture by limiting dilution for use in this study. The Dd2-
PfATP4T418N,P990R parasites and their matched parental para-
sites (from Ref. 2; for which data are shown in Table 1 and Figs.
6 and 7) were generously provided by Elizabeth Winzeler.
Parasiteswere cultured in human erythrocytes (31)with con-
tinuous shaking (32) and were synchronized by exposure of
cultures to sorbitol (33). The culture medium was RPMI 1640
medium containing 25 mMHEPES (Gibco) supplemented with
11mM additional glucose, 0.2mM hypoxanthine, 20g/ml gen-
tamicin sulfate, and 3 g/liter Albumax II.
Prior to preparing membranes, mature trophozoite-stage
parasites (34–40 h post-invasion) were functionally isolated
from their host erythrocytes by brief exposure (of cultures at
4% hematocrit) to saponin (0.05% w/v, of which 10% was
the active agent sapogenin) (34). The parasites were then
washed several times in bicarbonate-free RPMI 1640 medium
supplemented with 11 mM additional glucose, 0.2 mM hypox-
anthine, and 25 mM HEPES, pH 7.10.
Preparation of parasitemembranes
Membranes were prepared from saponin-isolated trophozo-
ite-stage parasites essentially as described previously (15).
Briefly, parasites were sedimented by centrifugation (12,000
g, 30 s) and then lysed in ice-cold deionized water containing
protease inhibitors (a 1:500 dilution of Protease Inhibitor Mix-
ture Set III; Merck Millipore). The membrane preparation was
then washed three times in ice-cold deionized water (14,000
g for 10min at 4 °C, with protease inhibitors present for the first
twowashes). The protein content in themembrane preparation
was measured using a modified Bradford assay (35). The mem-
brane preparation is likely to contain membrane from the host
erythrocyte and the parasite’s intracellular organelles, in addi-
tion to parasite plasma membrane.
ATPase assays
ATPase activity was quantified by measuring the production
of Pi from the hydrolysis of ATP, using the PiColorLock Gold
Phosphate Detection System (Innova Biosciences). Unless
stated otherwise in the relevant figure legends, the duration of
the reactions was 10 min, and the final reaction mixtures had a
pHof 7.2 and consisted of 20mMKCl, 2mMMgCl2, 50mMTris,
NaCl and/or choline chloride ([NaCl]  [choline chloride] 
150 mM), parasite membrane (final concentration of total pro-
tein 50g/ml), and 1mMATP (Na2ATP3H2O;MPBiomedi-
cals; added last to initiate the reaction).
To terminate the reaction, 100 l of each reaction mixture
was added (in duplicate) to 25 l of “Gold mix” in a 96-well
plate. “Stabilizer” was added 2–3 min later, and the plate was
incubated for 1 h before absorbance was measured at 635 nm.
Blank values (from wells containing only water, Gold mix, and
stabilizer) and control values (fromwells containing all compo-
nents, but to which ATP was not added until after the mem-
brane was exposed to Goldmix) were subtracted from the data.
PfATP4-associated ATPase activity was determined for each
condition by subtracting the data obtained in the presence of
500 nM cipargamin from that obtained in the absence of cipar-
gamin. For experiments in which a range of [Na] were tested,
a line was fitted to the data obtained over the range of [Na] in
the presence of cipargamin, and for each [Na] the ATPase
activity estimated from the fitted line (i.e. theATPase activity in
the presence of cipargamin) was subtracted from the ATPase
activity measured at the corresponding [Na] in the absence of
cipargamin to yield the PfATP4-associated ATPase activity.
Parasite proliferation assays
Parasite proliferation assays were commenced with P. falcip-
arum cultures adjusted to 1% parasitemia (consisting of pre-
dominantly ring-stage parasites) and 1% hematocrit. Parasite
proliferation was determined using a DNA-intercalating fluo-
rescent dye (36) after a 72-h incubation with the compound of
interest, using a method detailed previously (37).
Statistics and fitted curves
Statistical comparisons were performed using either t-tests
or one-way ANOVAs (as stated in the relevant sections).
ANOVAswere performed inGenStat (15th edition). In the case
PfATP4-associated Na-ATPase activity in Plasmodium
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of data that are presented as a percentage of a control value (Fig.
5, a, c, and e, and Fig. S1) ANOVAs were performed with the
pre-normalized data, and the “experiment” was nominated as a
“blocking factor.” The least significant difference test was used
for post hoc comparisons. p values  0.05 indicate statistical
significance.
In those cases in which equations were fitted to data to yield
estimates of fitted constants the relevant equations are speci-
fied. In those cases in which curves are fitted simply to serve as
illustrative trend lines, the underlying (arbitrary) equations are
not specified.
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